Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A 505(b)(2) program relying on literature plus a bridging study cannot treat an FAERS cluster in a demographic the trials under-enrolled as incidental context on RWE protocol that may not meet regulator expectations. Clinical-development physician must close to drop a secondary from that extract under Pharma & Life Sciences / Pharmacovigilance.

DECISION Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. Clinical-development physician can defend Proceed under protocol from RWE protocol that may not meet regulator expectations after an FAERS cluster in a demographic the trials under-enrolled in a Pharma & Life Sciences challenge. 2. Clinical-development physician cannot defend Proceed under protocol from RWE protocol that may not meet regulator expectations; Pause the pathway is what the extract actually supports after an FAERS cluster in a demographic the trials under-enrolled. 3. An FAERS cluster in a demographic the trials under-enrolled never reached the population in RWE protocol that may not meet regulator expectations — reopen intake, do not close to drop a secondary. 4. Two facts in RWE protocol that may not meet regulator expectations after an FAERS cluster in a demographic the trials under-enrolled conflict for clinical-development physician; hold this Pharmacovigilance file.

ANALYSIS REQUIRED 1. Check whether RWE protocol that may not meet regulator expectations supports the labeled claim clinical-development physician would keep. 2. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 3. Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after an FAERS cluster in a demographic the trials under-enrolled. 4. For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (RWE protocol that may not meet regulator expectations after an FAERS cluster in a demographic the trials under-enrolled). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after an FAERS cluster in a demographic the trials under-enrolled, then the two facts that force it, then the Monday action for clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study.